Onco-Hu® Models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells to help destroy cancers in vivo.
Human peripheral blood mononuclear cell-engrafted NSG™ and NSG™-SGM3 mice are perfect for short-term experiments requiring mature T cells, including HIV infection, immuno-oncology, and graft-versus-host disease studies.
Female NSG™ mice are injected with human peripheral blood mononuclear cells (hu-PBMCs). Mice can be shipped to the customer within days of engraftment. Engraftment (principally T cells) can increase over time, but it is limited by the development of graft-versus-host disease.
Study-ready cohorts of hu-PBMC humanized mice are provided upon request, either for shipment to your institution or for enrollment in customized drug efficacy studies executed by our In Vivo Services scientists.
We distribute NSG™ mice under an agreement with the NIH. NSG™ mice are available to non-profit research institutions under an MTA. Companies and for profit entities require a license prior to shipping. Many companies already have a license that includes engrafted NSG™ mice. To confirm that your company is covered or for new license inquiries, please contact:
Director, Technology Transfer
The Jackson Laboratory